These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 17885551)

  • 1. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.
    Bhatnagar V; O'Connor DT; Schork NJ; Salem RM; Nievergelt CM; Rana BK; Smith DW; Bakris GL; Middleton JP; Norris KC; Wright JT; Cheek D; Hiremath L; Contreras G; Appel LJ; Lipkowitz MS
    J Hypertens; 2007 Oct; 25(10):2082-92. PubMed ID: 17885551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.
    Zivko M; Kusec R; Galesić K
    Coll Antropol; 2013 Sep; 37(3):765-70. PubMed ID: 24308214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients.
    Yu H; Zhang Y; Liu G
    Hypertens Res; 2003 Nov; 26(11):881-6. PubMed ID: 14714579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-gene interaction between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and antihypertensive therapy.
    Schelleman H; Klungel OH; van Duijn CM; Witteman JC; Hofman A; de Boer A; Stricker BH
    Ann Pharmacother; 2006 Feb; 40(2):212-8. PubMed ID: 16449550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of renin angiotensin system (RAS) candidate gene polymorphisms with response to Ramipril in patients with essential hypertension.
    Gupta S; Chattopadhyaya I; Agrawal BK; Sehajpal PK; Goel RK
    J Postgrad Med; 2015; 61(1):21-6. PubMed ID: 25511213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition.
    Harrap SB; Tzourio C; Cambien F; Poirier O; Raoux S; Chalmers J; Chapman N; Colman S; Leguennec S; MacMahon S; Neal B; Ohkubo T; Woodward M;
    Hypertension; 2003 Sep; 42(3):297-303. PubMed ID: 12925557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin angiotensin system blockage associates with insertion/deletion polymorphism of angiotensin-converting enzyme in patients with hypertensive emergency.
    Vilela-Martin JF; Vaz-de-Melo RO; Cosenso-Martin LN; Kuniyoshi CH; Yugar-Toledo JC; Pinhel MA; de Souza GF; Souza DR; Pimenta E; Moreno H; Cipullo JP
    DNA Cell Biol; 2013 Sep; 32(9):541-8. PubMed ID: 23869738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition.
    Hingorani AD; Jia H; Stevens PA; Hopper R; Dickerson JE; Brown MJ
    J Hypertens; 1995 Dec; 13(12 Pt 2):1602-9. PubMed ID: 8903618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
    Nordestgaard BG; Kontula K; Benn M; Dahlöf B; de Faire U; Edelman JM; Eliasson E; Fyhrquist F; Hille DA; Ibsen H; Lyle PA; Berg K; Sandberg M; Sethi AA; Wong PH; Os I
    Pharmacogenet Genomics; 2010 Feb; 20(2):77-85. PubMed ID: 20065889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haplotype of growth hormone and angiotensin I-converting enzyme genes, serum angiotensin I-converting enzyme and ventricular growth: pathway inference in pharmacogenetics.
    Huang S; Chen XH; Payne JR; Pennell DJ; Gohlke P; Smith MJ; Day IN; Montgomery HE; Gaunt TR
    Pharmacogenet Genomics; 2007 Apr; 17(4):291-4. PubMed ID: 17496728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
    Arnett DK; Davis BR; Ford CE; Boerwinkle E; Leiendecker-Foster C; Miller MB; Black H; Eckfeldt JH
    Circulation; 2005 Jun; 111(25):3374-83. PubMed ID: 15967849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor.
    Li X; Du Y; Du Y; Huang X
    J Cardiovasc Pharmacol Ther; 2003 Mar; 8(1):25-30. PubMed ID: 12652327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of A-240T and A2350G related genotypes of angiotensin-converting enzyme (ACE) is associated with decreased serum ACE activity and blood pressure in a healthy Iranian population.
    Firouzabadi N; Tajik N; Shafiei M; Ebrahimi SA; Bakhshandeh H
    Eur J Pharmacol; 2011 Oct; 668(1-2):241-7. PubMed ID: 21810419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension.
    Anthony EG; Richard E; Lipkowitz MS; Bhatnagar V
    Pharmacogenet Genomics; 2015 Sep; 25(9):444-9. PubMed ID: 26111150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.
    van der Kleij FG; Schmidt A; Navis GJ; Haas M; Yilmaz N; de Jong PE; Mayer G; de Zeeuw D
    Kidney Int Suppl; 1997 Dec; 63():S23-6. PubMed ID: 9407415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: a 12-year follow-up study.
    Lee JK; Wu CK; Tsai CT; Lin LY; Lin JW; Chien KL; Hwang JJ; Lin CL; Tseng CD; Chiang FT
    Pharmacogenet Genomics; 2013 Apr; 23(4):181-9. PubMed ID: 23407050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors.
    Danilov SM; Tovsky SI; Schwartz DE; Dull RO
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):374-386. PubMed ID: 28587581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of angiotensin converting enzyme (
    Ramanathan G; Ghosh S; Elumalai R; Periyasamy S; Lakkakula BV
    Indian J Med Res; 2016 Jun; 143(6):748-755. PubMed ID: 27748299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman KP; Nyström F; Hägg A; Lind L;
    J Hypertens; 2001 Oct; 19(10):1783-7. PubMed ID: 11593098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.